Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-03-29 Share Issue/Capital Cha…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Ökning av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document is a short press release (1640 characters) dated March 29, 2019, titled 'Ökning av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)' (Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ)). It explicitly states that the number of shares and votes has increased due to a directed new share issue ('riktad nyemission') completed in March 2019, detailing the exact increase in shares and share capital. This directly relates to a change in the company's capital structure via new share issuance. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it fits a specific category, and it is not an announcement of a report (RPA) because it contains the core information itself.
2019-03-29 Swedish
Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing a specific corporate action: an 'Increase in the number of shares and votes' following a directed new share issue. This directly relates to changes in the company's capital structure, specifically the number of outstanding shares and the share capital amount. Based on the definitions, the most appropriate category is 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not an earnings release (ER), a dividend notice (DIV), or a general regulatory filing (RNS), as it concerns a specific capital event.
2019-03-29 English
The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.
Report Publication Announcement Classification · 98% confidence The document is a short press release (3618 characters) announcing that clinical study data for the drug Apealea has been summarized in a manuscript and is now being published in a peer-reviewed journal ('Advances in Therapy'). The text includes standard press release elements: company boilerplate ('About Oasmia'), contact information, and a concluding statement about regulatory obligation ('EU Market Abuse Regulation'). Crucially, it contains an 'Attachment' link labeled 'PR Article EN 190328'. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or release of another document is classified as a Report Publication Announcement (RPA). It is not the full clinical data report itself, nor is it a standard regulatory filing like 10-K or ER.
2019-03-28 English
Resultaten från Oasmia Pharmaceuticals första studie med paklitaxel micellär i människa publiceras i den vetenskapliga tidskriften ”Advances in Therapy”.
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2019, announcing that the results from Oasmia Pharmaceutical's Phase I study (OAS-04-01) for their drug Apealea have been published in the scientific journal 'Advances in Therapy'. It includes quotes from the CEO and contact information. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific/clinical data being made public. Since it is a specific announcement regarding clinical/scientific findings being published, and it doesn't fit neatly into the other categories (like DIV, CAP, or MANG), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory or significant company announcements not covered elsewhere, especially when the core content is an external publication notice. Given the context of financial reporting databases, this type of scientific publication announcement is often categorized broadly if a more specific 'Clinical Trial Result Announcement' code is unavailable. RNS is the most appropriate general regulatory announcement code here.
2019-03-28 Swedish
The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.
Regulatory Filings Classification · 95% confidence The document is a short press release dated March 28, 2019, announcing that the results from a specific clinical study (OAS-04-01) involving their drug Apealea have been published in the scientific journal 'Advances in Therapy'. It provides context about the study and quotes the CEO, but it is not the full financial report (10-K, IR), nor is it a standard earnings release (ER) or a formal regulatory filing detailing financial performance. Since the core purpose is announcing the publication of scientific/clinical data, and it doesn't fit the specific categories like Audit Report (AR) or Management Discussion (MDA), it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement regarding published data, or potentially a Legal Proceedings Report (LTR) if the publication was mandated, but RNS is the most appropriate fallback for general corporate news that isn't strictly financial or governance-related. Given the context of publishing clinical data, RNS is the best fit as a general regulatory announcement.
2019-03-28 English
Notification from Oasmia Pharmaceutical AB
Legal Proceedings Report Classification · 99% confidence The document is very short (1749 characters) and announces that the 'Swedish Securities Council has today published a statement regarding Oasmia' and provides a link to that statement. It also includes an 'Attachment' link to a document named 'PR AMN 190326 EN'. This structure—announcing the publication of external information or a report and providing a link—strongly indicates a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), based on the 'MENU VS MEAL' rule. Since it is specifically announcing the publication of a statement/report, RPA is the most precise fit, as RNS is the fallback. It is not the statement itself, nor is it a specific type like 10-K, ER, or DIV.
2019-03-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.